The groundbreaking success of the copyright undeniably reshaped the pharmaceutical landscape, but investing in companies primarily reliant on generic versions presents a challenging picture. While early returns were impressive, the cessation of patents and the appearance of less expensive alternatives have diminished the customer base. Therefore, a